SR 2D micro-XRF imaging on entire rat thin sections in view of a pharmacokinetic study of a new bromine containing drug agains tuberculosis

Abstract

Tuberculosis (TB) is a common and often deadly infectious disease caused by various strains of mycobacteria, usually Mycobacterium tuberculosis in humans. Because of population growth, the absolute number of new cases is still increasing. Multi-drug-resistant tuberculosis (MDR-TB) is defined as resistance to the two most effective first-line TB drugs and is a public health issue in many developing countries, as treatment is longer and requires more expensive drugs. Recently, a new experimental diarylquinoline anti-tuberculosis drug was discovered at Janssen Pharmaceutica, referred to as TMC207 and shown in Fig. 1. Before TMC207 can be made commercially available, one of the necessary investigations is a thorough pharmacokinetic study to investigate its absorption, distribution, metabolism and excretion (ADME)